| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035310 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL |
01/01/2021 |
23.91 |
502.17 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035305 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL |
01/01/2021 |
11.95 |
251.09 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208062901 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL |
01/01/2021 |
22.01 |
462.10 |
01/13/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208062902 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL |
01/01/2021 |
11.51 |
241.61 |
01/13/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208044605 |
BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL |
01/01/2021 |
10.77 |
190.29 |
01/09/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208000401 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 2.5mL |
01/01/2021 |
10.96 |
193.73 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208000403 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 5mL |
01/01/2021 |
21.93 |
387.43 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208080060 |
LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg, 60 Sterile Ophthalmic Inserts |
01/01/2021 |
31.89 |
563.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050307 |
LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g |
01/01/2021 |
12.13 |
214.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208044335 |
LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g |
01/01/2021 |
17.07 |
301.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029910 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL |
01/01/2021 |
30.24 |
534.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029915 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL |
01/01/2021 |
44.95 |
794.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029905 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL |
01/01/2021 |
15.12 |
267.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208060203 |
PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL |
01/01/2021 |
16.96 |
299.63 |
11/11/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081205 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL |
01/01/2021 |
11.07 |
195.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081310 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL |
01/01/2021 |
15.35 |
271.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081305 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL |
01/01/2021 |
11.98 |
211.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081425 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL |
01/01/2021 |
12.95 |
228.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081605 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL |
01/01/2021 |
14.19 |
250.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050402 |
VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL |
01/01/2021 |
12.13 |
214.38 |
10/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050405 |
VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 5mL |
01/01/2021 |
24.27 |
428.77 |
10/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208053535 |
ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%), 5mL |
01/01/2021 |
22.34 |
394.68 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035810 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL |
01/01/2021 |
31.47 |
555.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035805 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL |
01/01/2021 |
15.74 |
277.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581030 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct |
01/01/2021 |
117.61 |
1606.27 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581130 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct |
01/01/2021 |
155.03 |
2117.46 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581230 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct |
01/01/2021 |
352.80 |
4818.71 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006410 |
ATIVAN® Tablets 1mg 1,000s |
01/01/2021 |
2756.36 |
37647.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006301 |
ATIVAN® Tablets .5mg 100s |
01/01/2021 |
210.68 |
2877.54 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006401 |
ATIVAN® Tablets 1mg 100s |
01/01/2021 |
281.44 |
3843.97 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006501 |
ATIVAN® Tablets 2mg 100s |
01/01/2021 |
448.52 |
6126.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
25010030515 |
DEMSER® (metyrosine), 250mg Capsules, 100ct |
01/01/2021 |
2210.87 |
39058.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187410010 |
LIBRAX Oral Capsule 5-2.5 MG (Chlordiazepoxide Hydrochloride and Clidinium Bromide), 100ct |
01/01/2021 |
362.02 |
4944.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301220 |
MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle |
01/01/2021 |
78.88 |
1393.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301030 |
MESTINON 60mg TABLETS 100s (pyridostigmine bromide) |
01/01/2021 |
97.11 |
1715.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301330 |
MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT |
01/01/2021 |
55.26 |
976.21 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
66490069110 |
MYSOLINE 250 mg TABLETS, 100s (primidone) |
01/01/2021 |
403.73 |
5514.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
66490069010 |
MYSOLINE 50 mg TABLETS, 100s (primidone) |
01/01/2021 |
117.32 |
1602.38 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187305050 |
ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump |
01/01/2021 |
35.56 |
628.27 |
08/05/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187442010 |
PEPCID® (Famotidine) Tablets, 20mg, 100 |
01/01/2021 |
89.73 |
1225.53 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187442030 |
PEPCID® (Famotidine) Tablets, 20mg, 30 |
01/01/2021 |
26.92 |
367.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187444010 |
PEPCID® (Famotidine) Tablets, 40mg, 100 |
01/01/2021 |
173.43 |
2368.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187444030 |
PEPCID® (Famotidine) Tablets, 40mg, 30 |
01/01/2021 |
52.02 |
710.58 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187149825 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct |
01/01/2021 |
26.60 |
469.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187149605 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL, 60ct |
01/01/2021 |
30.33 |
535.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073030 |
WELLBUTRIN® XL 150mg Tablets, 30ct |
01/01/2021 |
116.11 |
1585.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073090 |
WELLBUTRIN® XL 150mg Tablets, 90ct |
01/01/2021 |
348.36 |
4757.94 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073130 |
WELLBUTRIN® XL 300mg Tablets, 30ct |
01/01/2021 |
153.27 |
2093.43 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187045302 |
ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct |
01/01/2021 |
274.38 |
4847.28 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002260 |
Belbuca 150 mcg, film, 60ct box |
01/01/2021 |
17.44 |
366.26 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002360 |
Belbuca 300 mcg, film, 60ct box |
01/01/2021 |
27.39 |
575.22 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
437.53 |
401.40 |
2015 |
401.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002460 |
Belbuca 450 mcg, film, 60ct box |
01/01/2021 |
37.22 |
781.58 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
594.49 |
545.40 |
2015 |
545.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002560 |
Belbuca 600 mcg, film, 60ct box |
01/01/2021 |
39.71 |
834.00 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
634.38 |
582.00 |
2015 |
582.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002160 |
Belbuca 75 mcg, film, 60ct box |
01/01/2021 |
17.44 |
366.26 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002660 |
Belbuca 750 mcg, film, 60ct box |
01/01/2021 |
41.76 |
877.00 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
667.08 |
612.00 |
2015 |
612.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002760 |
Belbuca 900 mcg, film, 60ct box |
01/01/2021 |
42.99 |
902.79 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
686.70 |
630.00 |
2015 |
630.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385004130 |
Symproic .2mg mg tablet, 30 ct bottle |
01/01/2021 |
18.86 |
395.97 |
11/11/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/04/2019 |
Shionogi Inc. |
30000000 |
None |
None |
313.95 |
313.95 |
2017 |
313.95 |
None |
None |
| Rx0000099 |
Biogen |
03/31/2021 |
64406000801 |
TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial |
01/01/2021 |
372.31 |
7463.99 |
03/05/2027 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tysabri was not acquired by Biogen from another company in the last 5 years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597000201 |
APTIVUS 100MG/ML SOLUTION 95 |
01/01/2021 |
23.64 |
614.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=471 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597000302 |
APTIVUS 250MG CAPSULE 120 |
01/01/2021 |
70.93 |
1844.29 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=472 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597008717 |
ATROVENT HFA 17mcg Canister 12.9 |
01/01/2021 |
16.46 |
427.85 |
01/17/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=482 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003134 |
CATAPRES TTS-1 0.1mg PATCH 4 |
01/01/2021 |
11.16 |
290.24 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=476 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003234 |
CATAPRES TTS-2 0.2mg PATCH 4 |
01/01/2021 |
18.80 |
488.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=477 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003334 |
CATAPRES TTS-3 0.3mg PATCH 4 |
01/01/2021 |
26.07 |
677.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=478 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597002402 |
COMBIVENT RESPIMAT 20-100mcg Cartridge 4 |
01/01/2021 |
17.06 |
443.51 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=473 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014130 |
GILOTRIF 20MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=495 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597013730 |
GILOTRIF 30MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=490 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597013830 |
GILOTRIF 40MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=491 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015230 |
JARDIANCE 10MG TABLET 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=504 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015237 |
JARDIANCE 10MG TABLET 3x10 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=505 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015290 |
JARDIANCE 10MG TABLET 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=506 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015330 |
JARDIANCE 25MG TABLET 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=507 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015337 |
JARDIANCE 25MG TABLET 3x10 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=508 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015390 |
JARDIANCE 25MG TABLET 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=509 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014818 |
JENTADUETO 2.5MG-1000MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=502 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014860 |
JENTADUETO 2.5MG-1000MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=503 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014618 |
JENTADUETO 2.5MG-500MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=498 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014660 |
JENTADUETO 2.5MG-500MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=499 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014718 |
JENTADUETO 2.5MG-850MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=500 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014760 |
JENTADUETO 2.5MG-850MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=501 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027094 |
JENTADUETO XR 2.5MG-1000MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=523 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027073 |
JENTADUETO XR 2.5MG-1000MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=522 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027533 |
JENTADUETO XR 5MG-1000MG Tablet 30 |
01/01/2021 |
23.12 |
485.46 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=524 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027581 |
JENTADUETO XR 5MG-1000MG Tablet 90 |
01/01/2021 |
69.35 |
1456.37 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=525 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010930 |
MIRAPEX ER 0.375MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=486 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028530 |
MIRAPEX ER 0.75MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=528 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011330 |
MIRAPEX ER 1.5MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=487 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028630 |
MIRAPEX ER 2.25MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=529 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011530 |
MIRAPEX ER 3.0MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=488 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028730 |
MIRAPEX ER 3.75MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=530 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011630 |
MIRAPEX ER 4.5MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=489 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003001 |
MOBIC 15MG TABLET 100 |
01/01/2021 |
54.71 |
1422.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=475 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597002901 |
MOBIC 7.5MG TABLET 100 |
01/01/2021 |
35.78 |
930.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=474 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014360 |
OFEV 100MG CAPSULE 60 |
01/01/2021 |
629.07 |
11113.60 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=496 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014560 |
OFEV 150MG CAPSULE 60 |
01/01/2021 |
629.07 |
11113.60 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=497 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010854 |
PRADAXA 110MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=484 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010860 |
PRADAXA 110MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=485 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597036082 |
PRADAXA 150MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=540 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597036055 |
PRADAXA 150MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=539 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597035556 |
PRADAXA 75MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=538 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597035509 |
PRADAXA 75MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=537 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597019705 |
PRAXBIND 2.5g/50mL Vials 2 |
01/01/2021 |
272.46 |
4279.26 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=521 |
For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007541 |
SPIRIVA HANDIHALER 18mcg Blister Card 30 |
01/01/2021 |
22.76 |
478.00 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=479 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007575 |
SPIRIVA HANDIHALER 18mcg Blister Card 5 |
01/01/2021 |
4.51 |
94.67 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=481 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007547 |
SPIRIVA HANDIHALER 18mcg Blister Card 90 |
01/01/2021 |
68.29 |
1434.01 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=480 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016061 |
SPIRIVA RESPIMAT 1.25mcg Cartridge 4 |
01/01/2021 |
22.76 |
478.00 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=513 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010061 |
SPIRIVA RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
22.76 |
478.00 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=483 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015561 |
STIOLTO RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
16.86 |
438.38 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=510 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597019261 |
STRIVERDI RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
8.98 |
233.52 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=520 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016818 |
SYNJARDY 12.5-1000MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=514 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016860 |
SYNJARDY 12.5-1000MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=515 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597018018 |
SYNJARDY 12.5-500MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=518 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597018060 |
SYNJARDY 12.5-500MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=519 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597017518 |
SYNJARDY 5-1000MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=516 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597017560 |
SYNJARDY 5-1000MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=517 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015918 |
SYNJARDY 5-500MG TABLET 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=511 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015960 |
SYNJARDY 5-500MG TABLET 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=512 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028073 |
SYNJARDY XR 10mg-1000mg Tablet 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=526 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028090 |
SYNJARDY XR 10mg-1000mg Tablet 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=527 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597030093 |
SYNJARDY XR 12.5mg-1000mg Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=536 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597030045 |
SYNJARDY XR 12.5mg-1000mg Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=535 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029588 |
SYNJARDY XR 25mg-1000mg Tablet 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=534 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029578 |
SYNJARDY XR 25mg-1000mg Tablet 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=533 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029059 |
SYNJARDY XR 5mg-1000mg Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=531 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029074 |
SYNJARDY XR 5mg-1000mg Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=532 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014061 |
TRADJENTA 5MG TABLET 100 |
01/01/2021 |
77.06 |
1618.19 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=493 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014030 |
TRADJENTA 5MG TABLET 30 |
01/01/2021 |
23.12 |
485.46 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=492 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014090 |
TRADJENTA 5MG TABLET 90 |
01/01/2021 |
69.35 |
1456.37 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=494 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089321 |
ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
28.25 |
499.07 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089331 |
ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets |
01/01/2021 |
47.09 |
831.85 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089470 |
ELIQUIS 5 MG Tablet Bottle of 74 Tablets |
01/01/2021 |
34.84 |
615.53 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003376474 |
ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs) |
01/01/2021 |
34.84 |
615.53 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089421 |
ELIQUIS 5 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
28.25 |
499.07 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089431 |
ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100 |
01/01/2021 |
47.09 |
831.85 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218851 |
ORENCIA 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218811 |
ORENCIA 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe , Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218713 |
ORENCIA 250 MG Solution Vial W/ Syringe, Package contains 1 Vial |
01/01/2021 |
52.90 |
1228.47 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003281411 |
ORENCIA 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003281811 |
ORENCIA 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085222 |
SPRYCEL 100 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085722 |
SPRYCEL 140 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052711 |
SPRYCEL 20 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
362.23 |
8411.82 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052811 |
SPRYCEL 50 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
724.46 |
16823.60 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052411 |
SPRYCEL 70 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
724.46 |
16823.60 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085522 |
SPRYCEL 80 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |